Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
p o n d e n c e Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline WorkersTo the Editor: Data are needed regarding the effectiveness of a third dose of a messenger RNA (mRNA) vaccine against the B.1.1.529(omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are based on scientifically rigorous, population-level surveillance.Health care personnel, first responders, and other essential and frontline workers who are being evaluated in the HEROES-RECOVER cohorts at eight sites in six states across the United States underwent weekly reverse-transcriptase-polymerase-chain-reaction (RT-PCR) testing regardless of the presence or absence of coronavirus disease 2019 (Covid-19) symptoms.1-3 Here, we report the vaccine effectiveness of two or three doses of an mRNA vaccine against infection caused by the omicron and B.1.617.2 (delta) variants.Methods for the HEROES-RECOVER studies have been published previously (with details provided in the Supplementary Appendix, available with the full text of this letter at NEJM.org).[1][2][3] Vaccination was documented by the workers through vaccine cards and medical records or state immunization information systems.Cohort participants could have received three doses of the BNT162b2 vaccine (Pfizer-BioNTech) (administered in 74%), the mRNA-1273 vaccine (Moderna) (in 24%), or a combination of the two vaccines (in 2%); recipients of the Ad26.COV2.S vaccine (Johnson & Johnson-Janssen) were excluded from the analysis.The study period began on August 26, 2021, shortly after the Food and Drug Administration recommended that recipients of the initial twodose mRNA vaccination series receive a third (booster) dose.Hazard ratios were estimated with the use of the Andersen-Gill extension of the Cox proportional-hazards model that accounts for time-varying vaccination status.We adjusted the estimates of vaccine effectiveness using inverse-propensity weighting.We performed SARS-CoV-2 whole-genome sequencing using published protocols.The study was reviewed and approved by the institutional review board at each participating study site or under reliance agreements.From the initiation of the study until January 22, 2022, we detected 202 infections with the delta variant and 419 with the omicron variant in samples obtained from 3241 participants.Among unvaccinated adults, the percentage of asymptomatic infection (no reported symptoms) this week's letters 1855 Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers 1857 Pulse Oximetry for Monitoring Patients with Covid-19 at Home -A Pragmatic, Randomized Trial 1860 Nivolumab with or without Relatlimab in Untreated Advanced Melanoma 1861 Tricuspid Repair in Patients with Degenerative Mitral Regurgitation 1863 Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery 1866 Medical Conditions and High-Altitude Travel 1867 Intrinsic Severity of the SARS-CoV-2 Omicron Variant
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Accorsi, E. K., Britton, A., Fleming-Dutra, K. E., Smith, Z. R., Shang, N., Derado, G., Miller, J., Schrag, S. J., & Verani, J. R. (2022) · JAMA · doi:10.1001/jama.2022.0470 · Cited by 628
Thompson, M. G., Natarajan, K., Irving, S. A., Rowley, E. A., Griggs, E. P., Gaglani, M., Klein, N. P., Grannis, S. J., DeSilva, M. B., Stenehjem, E., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7104e3 · Cited by 398
Self-citation
Research works printed but not linked: 3
- 10.1056/NEJMoa2107058 · DOI · Paper page
- 10.2196/31574 · DOI
- 10.2196/28925 · DOI
Cited by
Mohammed, H., Pham-Tran, D. D., Yeoh, Z. Y. M., Wang, B., McMillan, M., Andraweera, P. H., & Marshall, H. S. (2023) · Vaccines · doi:10.3390/vaccines11020224 · Cited by 47
Rahman, M. O., Kamigaki, T., Thandar, M. M., Haruyama, R., Yan, F., Shibamura-Fujiogi, M., Khin Maung Soe, J., Islam, M. R., Yoneoka, D., Miyahara, R., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-076892 · Cited by 29
Zhou, R., Liu, N., Li, X., Peng, Q., Yiu, C.-K., Huang, H., Yang, D., Du, Z., Kwok, H.-Y., Au, K.-K., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100660 · Cited by 26
Guo, K., Ni, P., Chang, S., Jin, Y., Duan, G., & Zhang, R. (2023) · American Journal of Infection Control · doi:10.1016/j.ajic.2023.02.005 · Cited by 12
Metadata
- Authors
- Yoon, S. K., Hegmann, K. T., Thiese, M. S., Burgess, J. L., Ellingson, K., Lutrick, K., Olsho, L. E. W., Edwards, L. J., Sokol, B., Caban-Martinez, A. J., Schaefer-Solle, N., Jones, J. M., Tyner, H., Hunt, A., Respet, K., Gaglani, M., Dunnigan, K., Rose, S., Naleway, A., Groom, H., Kuntz, J., Fowlkes, A. L., Thompson, M. G., & Yoo, Y. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-05-12
- Volume
- 386
- Issue
- 19
- Pages
- 1855-1857
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4224306527
- Cited by
- 41
- References
- 2
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases Grant (75D30120C08150, 75D30120C08379)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. https://app.cochat.ai/papers/10.1056/nejmc2201821
- The paper
- Yoon, S. K., Hegmann, K. T., Thiese, M. S., Burgess, J. L., Ellingson, K., Lutrick, K., Olsho, L. E. W., Edwards, L. J., Sokol, B., Caban-Martinez, A. J., Schaefer-Solle, N., Jones, J. M., Tyner, H., Hunt, A., Respet, K., Gaglani, M., Dunnigan, K., Rose, S., Naleway, A., . . . Yoo, Y. M. (2022). Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. New England Journal of Medicine. https://doi.org/10.1056/nejmc2201821
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.